Coronavirus Statement
Coronavirus Statement
The World Health Organisation (WHO), European Medicines Agency (EMA) & NHS state that there is currently no strong scientific evidence establishing a link between ibuprofen and worsening of COVID‑19.
Reckitt Benckiser (RB), the makers of Nurofen products, is aware of the ongoing spread of information, in the press and social media, concerning the use of steroids & non-steroidal anti-inflammatory (NSAIDs) products, including ibuprofen, for the alleviation of COVID-19 symptoms.
On 18th March 2020, The European Medicines Agency (EMA), World Health Organisation (WHO) as well as NHS confirmed that there is currently no strong scientific evidence linking ibuprofen usage to worsening of Covid-19.
Patients and healthcare professionals should consider each case separately:
- WHO does not recommend against the use of ibuprofen
- In line with EU national treatment guidelines, NSAIDs usage can continue as per the approved product information.
- Based on the above, there is currently no reason for patients taking ibuprofen to interrupt their treatment outside of doctor’s advice, especially if a patient is taking ibuprofen or another NSAID on the advice of a doctor
Consumer safety is our number one priority. Ibuprofen is a well-established medicine that has been used with a good safety profile as a fever and pain reducer for more than 30 years.
Based on all available information, we agree that there is currently no strong scientific evidence linking over-the-counter use of ibuprofen to the aggravation of COVID-19. As with any medicine, we would remind consumers and their caregivers to carefully read and follow the instructions provided on the packaging and in the patient information leaflet. If you have any additional concerns speak to your healthcare professional.
As a responsible, science-led organisation, we are engaging with the relevant health authorities. We remain committed to communicating any additional information or guidance necessary for the safe use of our products should the need arise.
Reference to full EMA statement: https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19